Research programme: antiviral therapeutics - Galapagos
Latest Information Update: 03 Mar 2015
At a glance
- Originator Galapagos NV
- Developer Galapagos NV; Rega Institute for Medical Research; University Hospital Heidelberg
- Mechanism of Action Viral protein inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Research Hepatitis B
Most Recent Events
- 12 Feb 2015 Early research in Hepatitis B in Belgium (unspecified route)